Ionis Pharmaceuticals vs PTC Therapeutics
IONS and PTCT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IONS and PTCT compare
Ionis Pharmaceuticals and PTC Therapeutics are about the same size, with market caps of $4.8B and $5.3B.
Ionis Pharmaceuticals grew revenue faster over the last twelve months (−0.71% versus −35.1% for PTC Therapeutics).
PTC Therapeutics keeps more of each dollar of sales as profit, with a net margin of −9.2% compared with −56.9% at Ionis Pharmaceuticals.
PTC Therapeutics scores higher on the StockData Score (5 against 3 for Ionis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IONS | PTCT |
|---|---|---|
| Size and price | ||
| Market cap | $4.8B | $5.3B |
| Share price | $29.06 | $63.49 |
| Change, 1 year | −60.0% | −15.3% |
| Change, 5 years | −9.2% | 58.7% |
| Beta (5Y) | 0.68 | 1.09 |
| Employees | 1,402 | 991 |
| StockData Score | ||
| Total score | 3 | 5 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 2 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.0× | 4.6× (better) |
| P/B | 12.3× | – |
| EV/EBITDA | – | 17.8× |
| P/FCF | – | 2566× |
| FCF yield | −12.8% | 0.04% (better) |
| Fair value | $27.99 | $48.37 |
| Margin of safety | −3.8% (better) | −31.3% |
| Growth | ||
| Revenue growth (TTM) | −0.71% (better) | −35.1% |
| Revenue growth, 5Y average | 5.3% | 35.4% (better) |
| Net income growth (TTM) | – | −114% |
| EPS growth (TTM) | – | −114% |
| Profitability | ||
| Gross margin | 98.2% | – |
| Operating margin | −58.8% | 12.8% (better) |
| Net margin | −56.9% | −9.2% (better) |
| FCF margin | −64.2% | 0.18% (better) |
| Return on equity | −108% | – |
| Financial health | ||
| Net debt / EBITDA | – | −7.63 |
| Interest coverage | −29.4× | – |
| Current ratio | 5.43 (better) | 3.27 |
| Altman Z-score | 0.22 | 0.83 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 108% | 120% |
| Held by insiders | 0.80% | 3.0% |
| Insider net buying, 12 months | −$114M | −$44.2M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 12.8% | 9.6% |
Go deeper
- IONS stock overview
- IONS income statement
- IONS valuation and score
- PTCT stock overview
- PTCT income statement
- PTCT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.